Guanidines pp 49-58 | Cite as

Developmental Changes in Guanidino Compounds Levels in Mouse Organs

  • Yoko Watanabe
  • Shoichiro Shindo
  • Akitane Mori


Many kinds of guanidino compounds are known to be existent in mammalian organsl, and they are thought to be related to nitrogen metabolism. There have been many reports of guanidino compound levels in human body fluids and animal organs changing under various pathological conditions. Methylguanidine (MG) and guanidinosuccinic acid (GSA) in serum are elevated in uremic patients2,3. Increased excretion of α-keto-δ-guanidinovaleric acid in urine was observed in patients with hyperargininaemia4. High concentrations of taurocyamine in the cerebrospinal fluid of some epileptic patients have been observed5. Yokoi et al.6,7 showed the homoarginine (HArg) level to be high in liver, kidney and serum of rats administered alcohol chronically. These observations suggest that guanidino compound levels in organs may change according to physiological conditions. It is possible that the levels of guanidino compounds may also change during maturation when physiological conditions are thought to be undergoing change. The data reported herein are the results of a study of developmental changes in the levels of guanidino compounds in mouse organs.


Urea Cycle Adult Level Suckling Period Mouse Organ Human Body Fluid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    A. Mori, Natural occurrence and analyses of guanidino compounds, Rinshokagaku 9: 232 (1980).Google Scholar
  2. 2.
    S. Giovannetti, P. L. Balestri and G. Barsotti, Methyl-guanidine in uremia, Arch. Intern. Med., 131: 709 (1973).PubMedCrossRefGoogle Scholar
  3. 3.
    I. M. Stein, B. D. Cohen and R. S. Kornhauser, Guanidinosuccinic acid in renal failure, experimental azotemia and in born errors of the urea cycle, New. Engl. J. Med., 280: 926 (1960).CrossRefGoogle Scholar
  4. 4.
    B. Marescau, J. Pintens, A. Lowenthal, E. Esmans, Y. Luyten,G. Lemiere, R. Dommisse, F. Alderweireldt, and H. G. Terheggen, Isolation and identification of 2-oxo-5guanidinovaleric acid in urine of patients with hyperargininaemia by chromatography and gas chromatography/mass spectrometry, J. Clin. Chem. Clin. Biochem., 19: 61 (1981).Google Scholar
  5. 5.
    A. Mori, Y. Watanabe and M. Akagi, Guanidino compound anomalies in epilepsy, in:“Advances in Epileptology: XIIIth Epilepsy International Symposium,” H. Akimoto,H. Kazamatsuri, M. Seino, and A. Ward, eds., Raven Press, New York (1982).Google Scholar
  6. 6.
    I. Yokoi, J. Toma and A. Mori, Effects of taurine on guanidino compounds in the brain and serum of rats administered alcohol chronically, Neurosciences 9: 177 (1983).Google Scholar
  7. 7.
    I. Yokoi, J. Toma and A. Mori, The effect of chronic ethanol administration on the guanidino compounds in rat organs, (in this book).Google Scholar
  8. 8.
    A. Mori, Y. Watanabe and N. Fujimoto, Fluorometrical analysis of guanidino compounds in human cerebrospinal fluid,J. Neurochem. 38:448 (1982).Google Scholar
  9. 9.
    H. Kato, I. Oyamada, M. Mizutani-Funahashi and H. Nakagawa, New radioisotopic assays of argininosuccinic synthetase and argininosuccinase, J. Biochem. 79:945 (1976).Google Scholar
  10. 10.
    J. G. Morris and Q. R. Rogers, Arginine: An essential amino acid for the cat, J. Nutr. 108:1944 (1978).Google Scholar
  11. 11.
    M. Funahashi, H. Kato, S. Shiosaka and H. Nakagawa, Formation of arginine and guanidinoacetic acid in the kidney in vivo.Their relations with the liver and their regulation, J. Biochem. 89:1347 (1981).Google Scholar
  12. 12.
    J. B. Walker, Formamidine group transfer in extracts of human pancreas, liver, and kidney, Biochim. Biophys. Acta,73:241 (1963).Google Scholar
  13. 13.
    A. Scott-Emuakpor, J. V. Higgins and A. F. Kohrman, Citrullinemia: A new case, with implications concerning adaptation to defective urea synthesis, Pediat. Res. 6:626 (1972).Google Scholar
  14. 14.
    N. C. Woody and Eng Bee Ong, Paths of lysine degradation in patients with hyperlysinemia, Pediatrics 40: 986 (1967).Google Scholar
  15. 15.
    S. Natelson, A. Koller, H. Tseng and R. F. Dods, Canaline carbamoyltransferase in human liver as part of a metabolic cycle in which guanidino compounds are formed, Clin. Chem. 23:960 (1977).Google Scholar
  16. 16.
    B. D. Cohen and H. Patel, Guanidinosuccinic acid and the alternate urea cycle, in:“Urea cycle diseases” A. Lowenthal, A. Mori, and B. Marescau, eds., Plenum Press, New York (1982).Google Scholar

Copyright information

© Springer Science+Business Media New York 1985

Authors and Affiliations

  • Yoko Watanabe
    • 1
  • Shoichiro Shindo
    • 1
  • Akitane Mori
    • 1
  1. 1.Department of Neurochemistry, Institute for NeurobiologyOkayama University Medical SchoolOkayama 700Japan

Personalised recommendations